Bio-Path Holdings
  • About Bio-Path
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Partnering Opportunities
  • Technology
  • Pipeline
    • Pipeline
    • Prexigebersen
    • BP1001-A
    • BP1002
    • BP1003
  • Patients
  • Investors
    • Overview
    • SEC Filings
    • Corporate Governance
  • Media
    • Press Releases
    • Events
    • Presentations & Publications
  • Careers
  • Contact Us

Webcast link to Corporate Update Conference Call on Thursday, May 29, 2025 at 8:30 a.m.

Bio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025

BPTH_Corporate_Update_Conference_Call_Announcement_20250522

SEC Form 10-Q: For Period ending March 31, 2025

BPTH_20250515_10-Q

SEC Form 8-K: Press Release dated May 1, 2025

BPTH_8-K_20250502

Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients

BP1001-A_Obesity_Third_Efficacy_Milestone

SEC Form 8-K: Entry into a Material Definitive Agreement

BPTH_8-K_20250429

SEC Form 1-A

BPTH_Form_1-A_20250411

SEC: Withdrawal of Registration Statement on Form S-1

BPTH_25-3664-12__RW_20250409

SEC Form 8-K: Entry into a Material Definitive Agreement

BPTH_8-K_25-10724

SEC Form 8-K: Press Release dated March 28, 2025

BPTH20250327_8-K

Bio-Path Holdings

All Rights Reserved

Office:

4710 Bellaire Blvd, Suite 210
Bellaire, TX 77401

T: (832) 742-1357

R&D:

5455 Dashwood Street, Suite 300
Bellaire, TX 77401

T: (832) 742-1357

logo
  • About Bio-Path
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Partnering Opportunities
  • Technology
  • Pipeline
    • Pipeline
    • Prexigebersen
    • BP1001-A
    • BP1002
    • BP1003
  • Patients
  • Investors
    • Overview
    • SEC Filings
    • Corporate Governance
  • Media
    • Press Releases
    • Events
    • Presentations & Publications
  • Careers
  • Contact Us